← Eichor
Study identifier: NCT04020263 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Effect of Early Use of Levosimendan Versus Placebo on Top of a Conventional Strategy of Inotrope Use on a Combined Morbidity-mortality Endpoint in Patients With Cardiogenic Shock

Condition: Cardiogenic Shock  ·  Sponsor: Pr Bruno LEVY

PhasePhase 3
Planned participants610
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Cardiogenic shock (CS) mortality remains high (40%). Despite their frequent use, few clinical outcome data are available to guide the initial selection of vasoactive drug therapies in patients with CS. Based on experts' opinions, the combination of norepinephrine-dobutamine is generally recommended as a first line strategy. Inotropic agents increase myocardial contractility, thereby increasing cardiac output. Dobutamine is commonly recommended to be the inotropic agent of choice and levosimendan is generally used following dobutamine failure. It may represent an ideal agent in cardiogenic shock, since it improves myocardial contractility without increasing cAMP or calcium concentration. At present, there are no convincing data to support a specific inotropic agent in patients with cardiogenic shock. Our hypothesis is that the early use of levosimendan, by enabling the discontinuation of dobutamine, would accelerate the resolution of signs of low cardiac output and facilitate myocardial recovery.

This description comes directly from the study's public registry record.

Talk to the study team

Bruno LEVY, Pr  ·  +33 3 83 15 40 84  ·  b.levy@chru-nancy.fr

Always discuss trial participation with your own doctor first.

Locations (28)

CHRU Strasbourg -Nouvel Hôpital CivilStrasbourg, Bas-Rhin, FranceRecruiting
AP-HM, Nord Hospital, MarseilleMarseille, Bouches du Rhône, FranceRecruiting
CHU CaenCaen, Calvados, FranceNot Yet Recruiting
CHU DijonDijon, Côte d'Or, FranceRecruiting
CHU Besançon Jean Minjoz HospitalBesançon, Doubs, FranceRecruiting
CHU Nîmes, Carémeau HospitalNîmes, Gard, FranceRecruiting
CHU Bordeaux - Hopital haut-levequeBordeaux, Gironde, FranceRecruiting
CHU de ToulouseToulouse, Haute-Garonne, FranceRecruiting
CHU Limoges, Dupuytren HospitalLimoges, Haute-Vienne, FranceRecruiting
CHU Montpellier, Arnaud de Villeneuve HospitalMontpellier, Hérault, FranceRecruiting
CHU Rennes, Pontchaillou HospitalRennes, Ille et Vilaine, FranceRecruiting
CHU Grenoble, Michallon HospitalLa Tronche, Isère, FranceRecruiting

+ 16 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04020263